Under terms of the agreement, Konica Minolta Opto (KMOT) will have a defined period of time to evaluate certain applications of Guided Therapeutics’s (GT’s) technology, including the potential adaptation of its LightTouch non-invasive cervical cancer detection technology to lung and biliary cancer. KMOT also will purchase prototype equipment and single use disposables.
Mark Faupel, president and CEO of GT, said: “The potential extension of our platform LightTouch technology into lung cancer detection may have a significant impact on this deadly cancer, which currently lacks cost effective and accurate methods for early detection.”